For anyone who loves kava — or is considering it for the first time — you’ve probably come across the liver safety question. It tends to circulate on forums and in news articles, often without much context. The short version usually goes: “kava was banned in Germany because it damaged people’s livers.”
That’s not quite the whole story.
In 2007, the World Health Organization commissioned an independent expert committee to do what no regulatory agency had done before: a full, rigorous, methodologically sound review of every available case report, clinical trial, and piece of safety literature on kava. The result — officially titled Assessment of the Risk of Hepatotoxicity with Kava Products — is one of the most comprehensive scientific reviews ever conducted on kava safety.
Here’s what they found.
The Liver Scare: What Actually Happened
Starting in the 1990s, cases of serious liver problems in people using kava products began appearing, primarily in Europe. By the end of 2002, the German Federal Institute for Drugs and Medical Devices had collected 40 case reports — six involving liver transplants and three fatalities. This triggered bans and product withdrawals across Germany, Switzerland, Australia, the UK, and Canada.
It was genuinely alarming. But what wasn’t asked loudly enough at the time was: what kind of kava were these people actually taking?
Almost universally, the answer was acetonic or ethanolic extract kava supplements — concentrated pills and capsules manufactured by European pharmaceutical companies. Almost none of the cases involved kava prepared and consumed the traditional way: as a water-based root drink.
That distinction turned out to be everything.
Traditional Water Kava vs. European Extract Pills: A Critical Chemical Difference
Kava root is a complex plant. Its active compounds — kavalactones — are what produce the relaxation and calm that kava is known for. When Pacific Islanders prepare traditional kava by grinding or pounding the root and mixing it with water, they get a drink that contains kavalactones in a natural suspension, along with protective compounds including glutathione — a peptide that helps the liver naturally process and detoxify kava compounds.
European pharmaceutical manufacturers took a very different approach. They used organic solvents — acetone or ethanol — to extract and concentrate kavalactones into pills and capsules. This process was efficient, but it also:
- Extracted additional compounds not present in traditional water kava, including flavokavins (pigments) and potentially hepatotoxic alkaloids like pipermethystine
- Lost glutathione entirely — the protective compound present in traditional water preparations
Making matters worse, many manufacturers chose to use stem peelings (civi civi in Fijian) rather than the root itself. Stem peelings cost about one-tenth the price of kava root — but they contain significantly higher concentrations of alkaloids than the root. Research presented at the 2004 International Kava Conference suggested that pipermethystine from stem peelings may have contributed to the liver problems seen with European kava pills.
The WHO committee put it plainly: “It is clear that water extracts as taken in the South Pacific, with hardly any serious kava-related hepatotoxicity reported, are chemically different from the ‘kava’ used to make kava pills in Europe, and this difference could be responsible for the reported hepatotoxicity in some kava pill takers.”
3,000 Years of Traditional Use — With No Liver Problems
One of the most powerful data points in the WHO report is also the simplest: in thousands of years of traditional kava use across Pacific Island cultures, liver damage was never a reported concern.
A 2004 pilot study in Fiji evaluated the health of heavy traditional kava drinkers — people who had consumed an average of 100,000 bowls of kava over their lifetimes. The study found no association between kava consumption and liver disease. The researchers concluded that kava cannot be linked to liver disease when consumed in the traditional format — as water extracts.
A separate survey of traditional healers and biomedical practitioners in Samoa specifically asked about signs of liver malfunction (yellowing of the eyes, brown urine, changes in stool) in kava drinkers. No one reported major clinical signs of liver malfunction in association with kava drinking.
That track record matters. Traditional kava is among the most thoroughly observed plant substances in the Pacific, used in ceremonial, social, and therapeutic contexts by millions of people across generations. The absence of liver concerns in that long history is not a coincidence — it reflects something real about how traditionally prepared noble kava interacts with the body.
What Clinical Trials Found
The WHO committee reviewed every available clinical trial involving kava. Their conclusion on this point is clear: “Clinical trials of kava have not revealed any hepatotoxicity.”
They analyzed sixteen or more well-controlled, double-blind studies examining kava for anxiety and other uses. Adverse events across these trials were consistently described as “mild, transient, and infrequent.” A Cochrane Library meta-analysis of 11 high-quality trials found that kava was effective for anxiety and “relatively free of side effects” compared to many conventional treatments, and notably, it is not addictive.
In two trials, minor elevations of liver enzymes were noted — but these were considered clinically insignificant and resolved on their own once kava use stopped.
What the 93 Case Reports Actually Showed
The WHO committee reviewed 93 case reports — the most comprehensive collection assembled at that time, drawn from regulatory agencies in Germany, Switzerland, the US, UK, Brazil, and elsewhere. Here’s what the pharmacovigilance analysis actually revealed:
- The majority were incomplete or unassessable due to missing information
- Only 8 cases were coded as “probable” — meaning essential information was present, a close association was established, and no other plausible cause could be identified
- Most patients were using acetonic or ethanolic extract products, not traditional water kava
- Many cases involved pre-existing liver conditions, heavy alcohol use, or concurrent use of other hepatotoxic medications
- Patients taking organic solvent extracts showed a higher rate of liver events than patients taking synthetic single-kavalactone products — a difference independent of age, gender, dose, or alcohol use
The committee also noted that many of the original German case reports had been criticized by independent reviewers for duplicate entries, missing clinical data, and “improbable temporal relationships between ingestion and the adverse event.” One independent analysis concluded that only three cases had any likelihood of kava-related hepatotoxic effects — and in two of those three, patients were taking dosages far beyond recommendations.
Risk Factors That Matter
For the rare cases where a kava association was plausible, the WHO committee identified clear risk factors that distinguished those cases from typical kava use:
- Use of acetonic or ethanolic extract products (pills or capsules)
- Pre-existing liver disease or history of hepatitis
- Heavy alcohol consumption
- Genetic differences in cytochrome P450 enzymes that affect how kava is metabolized
- Co-medication with other hepatotoxic drugs, especially certain anxiolytics, antipsychotics, and antithrombotics
- Excessive dosage well beyond recommended levels
None of these apply to someone drinking traditionally prepared noble kava root at moderate, normal levels.
What the WHO Concluded
The WHO committee’s overall conclusion supports what Pacific Island cultures have known for centuries: kava consumed in its traditional form — prepared from noble kava root as a water extract — has a strong and well-documented safety record. The liver concerns that emerged in Europe were primarily associated with a specific class of products: highly concentrated organic solvent extracts, often made from inferior plant material including stem peelings, that are chemically distinct from traditional kava.
The WHO recommended that any kava product use only the root or rhizome of Piper methysticum, exclude aerial plant parts and stem peelings, and prioritize water-based preparations. They identified quality control and sourcing standardization as essential to safety — and pointed out that the rapid commercialization of kava in Europe during the 1990s, with inadequate quality controls, likely contributed to the problems that emerged.
What This Means When You Buy Kava
This is why sourcing and quality matter so much to us at Kava.com.
Every product we carry is made from noble kava cultivars — the time-honored, traditionally used varieties that Pacific Islander communities have relied on for thousands of years. We source only from trusted farms in Hawaii, Fiji, Vanuatu, and the Solomon Islands where quality and varietal integrity are paramount. We use root — not stem peelings, not aerial plant parts.
When you prepare and drink our kava as a traditional water-based beverage, you’re experiencing kava the way it’s been safely enjoyed for millennia. The WHO’s findings affirm that this approach is the right one.
As always: if you have pre-existing liver disease, take medications metabolized by the liver, or drink heavily, have a conversation with your healthcare provider before adding kava to your routine. Kava is a powerful, respected plant with a remarkable history — and like anything worth respecting, it’s best enjoyed thoughtfully.
For more on kava safety, history, and how to get started, explore our Kava Library.
Source: World Health Organization. “Assessment of the Risk of Hepatotoxicity with Kava Products.” WHO Press, Geneva, 2007. ISBN 978 92 4 159526 1. Report prepared by an international expert committee including members from New Zealand, the University of the South Pacific (Fiji), and the Natural Standard Research Collaboration.
